Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0RJ1W
|
|||
| Former ID |
DIB004174
|
|||
| Drug Name |
OX-914
|
|||
| Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Phase 2 | [1] | |
| Company |
Inflazyme Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 4A (PDE4A) | Target Info | Inhibitor | [2] |
| Phosphodiesterase 4B (PDE4B) | Target Info | Inhibitor | [2] | |
| Phosphodiesterase 4D (PDE4D) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Purine metabolism | |||
| cAMP signaling pathway | ||||
| Morphine addiction | ||||
| NetPath Pathway | IL5 Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Pathwhiz Pathway | Purine Metabolism | |||
| Reactome | DARPP-32 events | |||
| G alpha (s) signalling events | ||||
| WikiPathways | G Protein Signaling Pathways | |||
| Myometrial Relaxation and Contraction Pathways | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Opioid Signalling | ||||
| TSH signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00758446) Efficacy and Safety Study of BLX-028914 in Subjects With Allergic Rhinitis. U.S. National Institutes of Health. | |||
| REF 2 | Orexo announces Phase IIa data on OX914 in rhinitis. Orexo. 24th March, 2009. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.